Diplomat Pharmacy (DPLO) Tops Q1 EPS by 4c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DPLO Hot Sheet
Join SI Premium – FREE
Diplomat Pharmacy (NYSE: DPLO) reported Q1 EPS of $0.19, $0.04 better than the analyst estimate of $0.15. Revenue for the quarter came in at $1.08 billion versus the consensus estimate of $1.08 billion.
GUIDANCE:
Diplomat Pharmacy sees FY2017 EPS of $0.54-$0.74, versus the consensus of $0.64. Diplomat Pharmacy sees FY2017 revenue of $4.3-4.7 billion, versus the consensus of $4.53 billion.
For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
